IL146003A0 - USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION - Google Patents

USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION

Info

Publication number
IL146003A0
IL146003A0 IL14600300A IL14600300A IL146003A0 IL 146003 A0 IL146003 A0 IL 146003A0 IL 14600300 A IL14600300 A IL 14600300A IL 14600300 A IL14600300 A IL 14600300A IL 146003 A0 IL146003 A0 IL 146003A0
Authority
IL
Israel
Prior art keywords
adrenergic receptor
sexual dysfunction
selective antagonists
improvement
sub
Prior art date
Application number
IL14600300A
Other languages
English (en)
Original Assignee
Recordati Chem Pharm
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recordati Chem Pharm filed Critical Recordati Chem Pharm
Publication of IL146003A0 publication Critical patent/IL146003A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/9433—(Nor)adrenaline
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Electrotherapy Devices (AREA)
IL14600300A 1999-05-07 2000-05-08 USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION IL146003A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI000995A IT1312310B1 (it) 1999-05-07 1999-05-07 Uso di antagonisti selettivi del recettore adrenergico a 1b per ilmiglioramento della disfunzione sessuale
PCT/EP2000/004308 WO2000067735A2 (en) 1999-05-07 2000-05-08 USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION

Publications (1)

Publication Number Publication Date
IL146003A0 true IL146003A0 (en) 2002-07-25

Family

ID=11382912

Family Applications (1)

Application Number Title Priority Date Filing Date
IL14600300A IL146003A0 (en) 1999-05-07 2000-05-08 USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION

Country Status (25)

Country Link
US (2) US6303606B1 (da)
EP (1) EP1177190B1 (da)
JP (1) JP2002544158A (da)
KR (1) KR100696755B1 (da)
CN (1) CN1150187C (da)
AT (1) ATE308538T1 (da)
AU (1) AU765487B2 (da)
BR (1) BR0010348A (da)
CA (1) CA2366201A1 (da)
DE (1) DE60023686T2 (da)
DK (1) DK1177190T3 (da)
ES (1) ES2250130T3 (da)
HK (1) HK1039900B (da)
HU (1) HUP0201184A3 (da)
IL (1) IL146003A0 (da)
IT (1) IT1312310B1 (da)
MX (1) MXPA01011261A (da)
NO (1) NO321841B1 (da)
NZ (1) NZ515240A (da)
PL (1) PL196708B1 (da)
RU (1) RU2239633C2 (da)
SI (1) SI1177190T1 (da)
TW (1) TWI224503B (da)
WO (1) WO2000067735A2 (da)
ZA (1) ZA200110042B (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014761A1 (en) * 1997-10-28 2004-01-22 Place Virgil A. Treatment of female sexual dysfunction with phosphodiesterase inhibitors
GB0000561D0 (en) * 2000-01-11 2000-03-01 Pfizer Ltd Treatment of diabetic ulcers
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
GB0225908D0 (en) * 2002-11-06 2002-12-11 Pfizer Ltd Treatment of female sexual dysfunction
US20070238762A1 (en) * 2003-09-15 2007-10-11 Diamedica Inc. Use of Antagonists of Hepatic Sympathetic Nerve Activity
US20050124625A1 (en) * 2003-10-21 2005-06-09 Salvati Mark E. Piperazine derivatives and their use as modulators of nuclear hormone receptor function
US20050260253A1 (en) * 2004-05-20 2005-11-24 Recordati Ireland Limited Transmucosal gel formulations
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
EP1802277B1 (de) * 2004-10-18 2010-01-13 Polymun Scientific Immunbiologische Forschung GmbH Liposomale zusammensetzung einen wirkstoff zur relaxierung glatter muskulatur enthaltend, die herstellung dieser zusammensetzung und deren therapeutische verwendung
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
CA2626134C (en) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
EP2037927B1 (en) 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin for the treatment of urinary incontinence and related diseases
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
JP5793828B2 (ja) 2006-08-14 2015-10-14 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フリバンセリンの製剤及びその製造方法
KR20090045945A (ko) 2006-08-25 2009-05-08 베링거 인겔하임 인터내셔날 게엠베하 제어 방출 시스템 및 이의 제조방법
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
CL2008002693A1 (es) 2007-09-12 2009-10-16 Boehringer Ingelheim Int Uso de flibanserina para el tratamiento de sintomas vasomotores seleccionados de sofocos, sudores nocturnos, cambios de estado de animo e irritabilidad
CN101592613B (zh) * 2009-07-06 2011-12-21 广东省药品检验所 一种中成药、保健食品和食品中添加pde5型抑制剂的检测方法
EA024099B1 (ru) 2010-09-13 2016-08-31 Оцука Фармасьютикал Ко., Лтд. Гетероциклические соединения для лечения или профилактики расстройств, вызываемых ослабленной нейротрансмиссией серотонина, норэпинефрина или допамина
WO2013137479A1 (en) * 2012-03-12 2013-09-19 Otsuka Pharmaceutical Co., Ltd. Decahydroquinoxaline derivatives and analogs thereof
US20130315891A1 (en) 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
US20130323222A1 (en) 2012-06-04 2013-12-05 Matthew Charles Human tissue kallikrein 1 glycosylation isoforms
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
SG11201811491YA (en) 2016-06-27 2019-01-30 Achillion Pharmaceuticals Inc Quinazoline and indole compounds to treat medical disorders
AU2018230478B2 (en) 2017-03-09 2025-01-23 Diamedica Inc. Dosage forms of tissue kallikrein 1

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5605897A (en) 1991-04-23 1997-02-25 Eli Lilly And Company 2-methyl-thieno-benzodiazepine
TW213903B (da) * 1991-08-16 1993-10-01 Boehringer Ingelheim Kg
GB9300059D0 (en) * 1992-01-20 1993-03-03 Zeneca Ltd Quinazoline derivatives
US5474994A (en) 1992-05-26 1995-12-12 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 -adrenergic and 5HT1A
IT1254469B (it) 1992-02-25 1995-09-25 Recordati Chem Pharm Derivati benzopiranici e benzotiopiranici
US5773457A (en) 1995-02-15 1998-06-30 Cesar Roberto Dias Nahoum Compositions
ES2146249T3 (es) 1993-02-10 2000-08-01 Bmra Corp Bv Composicion farmaceutica para tratar la impotencia que contiene un inhibidor alfa-1 y un inhibidor alfa-2.
US5565466A (en) 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
IT1270993B (it) 1994-03-18 1997-05-26 Recordati Chem Pharm Derivati chinzolilamminici attivi come alfa-antagonisti
CA2215307A1 (en) 1995-03-14 1996-09-19 Vivus, Incorporated Pharmaceutical compositions and kits for preventing erectile dysfunction
US5731339A (en) 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
JPH11512710A (ja) 1995-09-29 1999-11-02 メルク エンド カンパニー インコーポレーテッド アルファ１ｂアドレナリンレセプターアンタゴニスト
US5700364A (en) 1995-10-30 1997-12-23 Merck & Co., Inc. Electrochemical oxidation
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US5877216A (en) 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
JP2003525845A (ja) * 1997-10-28 2003-09-02 ヴィヴァス・インコーポレイテッド 勃起機能不全の処置のためのホスホジエステラーゼインヒビターの局所投与
CA2306837C (en) 1997-10-28 2007-05-08 Vivus, Inc. Treatment of female sexual dysfunction

Also Published As

Publication number Publication date
US6303606B1 (en) 2001-10-16
PL196708B1 (pl) 2008-01-31
NO20015428D0 (no) 2001-11-06
KR20020002494A (ko) 2002-01-09
DE60023686T2 (de) 2006-07-20
HK1039900B (en) 2006-02-03
HUP0201184A2 (en) 2002-10-28
AU765487B2 (en) 2003-09-18
SI1177190T1 (sl) 2006-02-28
WO2000067735A2 (en) 2000-11-16
NO321841B1 (no) 2006-07-10
KR100696755B1 (ko) 2007-03-19
JP2002544158A (ja) 2002-12-24
MXPA01011261A (es) 2002-08-12
CN1150187C (zh) 2004-05-19
DK1177190T3 (da) 2006-02-20
EP1177190B1 (en) 2005-11-02
NZ515240A (en) 2003-09-26
ZA200110042B (en) 2002-07-02
ATE308538T1 (de) 2005-11-15
CA2366201A1 (en) 2000-11-16
DE60023686D1 (de) 2005-12-08
ITMI990995A1 (it) 2000-11-07
PL351624A1 (en) 2003-05-19
EP1177190A2 (en) 2002-02-06
TWI224503B (en) 2004-12-01
US20020161009A1 (en) 2002-10-31
IT1312310B1 (it) 2002-04-15
US6953800B2 (en) 2005-10-11
WO2000067735A3 (en) 2001-02-01
BR0010348A (pt) 2002-02-13
HUP0201184A3 (en) 2003-05-28
HK1039900A1 (en) 2002-05-17
ES2250130T3 (es) 2006-04-16
AU4565400A (en) 2000-11-21
RU2239633C2 (ru) 2004-11-10
CN1354749A (zh) 2002-06-19
NO20015428L (no) 2001-11-06

Similar Documents

Publication Publication Date Title
IL146003A0 (en) USE OF SELECTIVE ANTAGONISTS OF THE α1b-ADRENERGIC RECEPTOR FOR IMPROVEMENT OF SEXUAL DYSFUNCTION
EP1027011A4 (en) ADMINISTRATION OF 5-HT RECEPTOR AGONISTS AND ANTAGONISTS INCLUDING ACTIVE SUBSTANCES FOR THE TREATMENT OF EARLY SEED EATING
HUP0204159A3 (en) Prostaglandin compositions and their use for preparation of pharmaceutical compositions for treatment male erectile dysfunction
NZ336436A (en) Solid dosage forms and method for ameliorating male erectile dysfunction
SG188700A1 (en) Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
IL172833A0 (en) Pyrimidine-2,4-dione derivatives and pharmaceutical compositions containing the same
YU20600A (sh) Nova upotreba antagonista 5-ht3 receptora
AU1192302A (en) Inhibition of emetic effect of metformin with 5-ht3 receptor antagonists
TNSN00199A1 (fr) PYRAZOLO [4,3-d] PYRIMIDINES-7-ONES PHARMACEUTIQUEMENT ACTIVES, LEUR PREPARATION ET MEDICAMENTS LES CONTENANT
AU7315301A (en) Compounds and compositions for delivering active agents
MY133423A (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders
UA41316C2 (uk) Трициклічні похідні піролу і фармацевтичний препарат
PL347671A1 (en) Compounds and compositions for delivering active agents
BR9911408A (pt) Formas de dosagem contendo apomorfina paramelhora de disfunção erétil masculina
HUP0301892A2 (hu) Szexuális zavarok kezelésére szolgáló gyógyszerkészítmények és előállításuk
MXPA01008611A (es) Compuestos y composiciones para suministrar agentes activos.
PL360254A1 (en) Pharmaceutical compositions
ATE428427T1 (de) Pyrimidin-2,4-dion-derivate als gonadotropin freisetzende hormon-rezeptor-antagonisten
AU2001285318A1 (en) Use of an aldosterone receptor antagonist to improve cognitive function
BG106602A (en) Formulation of substituted benzimidazoles
ZA200007019B (en) Use of prostaglandin agonists to treat erectile dysfunction or impotence.
DK1109814T3 (da) 5-Heterocyclylpyrazolo[4,3-d]pyrimidin-7-oner til behandling af mandlig erektil dysfunktion
NZ512137A (en) Prostaglandin E2 (PGE2) and PGE4 analogues, which are antagonists of the EP2 receptor for treatment of female sexual dysfunction
AU2003226765A8 (en) Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents
WO2002041894A3 (en) Selective dopamine d4 receptor agonists for treating sexual dysfunction